Efficacy and safety of adding immune checkpoint inhibitors to first-line standard therapy for recurrent or advanced cervical cancer: a meta-analysis of phase 3 clinical trials

HIGHLIGHTS

  • What: Data sources Frontiers in Immunology Data extraction and assessment of risk of bias Data pertinent to the study objectives were extracted by a primary investigator and subsequently verified for accuracy by an independent secondary reviewer.
  • Who: . and collaborators from the United States King Saud University, Saudi Arabia have published the Article: Ef fi cacy and safety of adding immune checkpoint inhibitors to rst-line standard therapy for recurrent or advanced cervical cancer: a meta-analysis of phase 3 clinical trials, in the Journal: (JOURNAL)
  • How: Given the need in the treatment landscape . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?